中国急救医学
中國急救醫學
중국급구의학
CHINESE JOURNAL OF CRITICAL CARE MEDICINE
2014年
9期
814-817
,共4页
张晶%王庆胜%杨红梅%马利祥%侯卫静%冯建双%刘晓媛
張晶%王慶勝%楊紅梅%馬利祥%侯衛靜%馮建雙%劉曉媛
장정%왕경성%양홍매%마리상%후위정%풍건쌍%류효원
急性心肌梗死%多支血管病变%冠状动脉介入治疗
急性心肌梗死%多支血管病變%冠狀動脈介入治療
급성심기경사%다지혈관병변%관상동맥개입치료
Acute myocardial infarction%Multivessel coronary artery disease%Percutaneous coronary intervention
目的:对急性心肌梗死( AMI)合并冠状动脉多支血管病变( MVD)患者,评估非梗死相关血管( non-IRA)的干预策略。方法本研究为前瞻性随机对照研究,选择2009-01~2011-06成功行急诊冠状动脉介入治疗( PCI)的302例符合入选标准AMI合并MVD患者,随机分为A组:近期( AMI后7~10 d) PCI干预non-IRA病变和B组:根据缺血证据行non-IRA PCI治疗。强调两组患者均根据指南施行最优化药物治疗。主要终点事件为再发心肌梗死、靶血管重建( TVR)和心因性死亡,次要终点事件为心因性再住院、心绞痛、心力衰竭、缺血相关的PCI治疗。结果共计288例患者完成24个月随访,A组145例,B组143例。其中A组和B组分别有12例和15例患者发生了主要终点事件( P=0.519),次要终点事件B组明显高于A组。在处理non-IRA过程中,两组均无围术期死亡发生。结论优化药物治疗基础上,AMI合并MVD患者近期干预non-IRA是安全的,能够明显降低心绞痛再发、心因性再住院和PCI的风险。但不能降低再梗死、靶血管重建、心因性死亡和心力衰竭的风险。
目的:對急性心肌梗死( AMI)閤併冠狀動脈多支血管病變( MVD)患者,評估非梗死相關血管( non-IRA)的榦預策略。方法本研究為前瞻性隨機對照研究,選擇2009-01~2011-06成功行急診冠狀動脈介入治療( PCI)的302例符閤入選標準AMI閤併MVD患者,隨機分為A組:近期( AMI後7~10 d) PCI榦預non-IRA病變和B組:根據缺血證據行non-IRA PCI治療。彊調兩組患者均根據指南施行最優化藥物治療。主要終點事件為再髮心肌梗死、靶血管重建( TVR)和心因性死亡,次要終點事件為心因性再住院、心絞痛、心力衰竭、缺血相關的PCI治療。結果共計288例患者完成24箇月隨訪,A組145例,B組143例。其中A組和B組分彆有12例和15例患者髮生瞭主要終點事件( P=0.519),次要終點事件B組明顯高于A組。在處理non-IRA過程中,兩組均無圍術期死亡髮生。結論優化藥物治療基礎上,AMI閤併MVD患者近期榦預non-IRA是安全的,能夠明顯降低心絞痛再髮、心因性再住院和PCI的風險。但不能降低再梗死、靶血管重建、心因性死亡和心力衰竭的風險。
목적:대급성심기경사( AMI)합병관상동맥다지혈관병변( MVD)환자,평고비경사상관혈관( non-IRA)적간예책략。방법본연구위전첨성수궤대조연구,선택2009-01~2011-06성공행급진관상동맥개입치료( PCI)적302례부합입선표준AMI합병MVD환자,수궤분위A조:근기( AMI후7~10 d) PCI간예non-IRA병변화B조:근거결혈증거행non-IRA PCI치료。강조량조환자균근거지남시행최우화약물치료。주요종점사건위재발심기경사、파혈관중건( TVR)화심인성사망,차요종점사건위심인성재주원、심교통、심력쇠갈、결혈상관적PCI치료。결과공계288례환자완성24개월수방,A조145례,B조143례。기중A조화B조분별유12례화15례환자발생료주요종점사건( P=0.519),차요종점사건B조명현고우A조。재처리non-IRA과정중,량조균무위술기사망발생。결론우화약물치료기출상,AMI합병MVD환자근기간예non-IRA시안전적,능구명현강저심교통재발、심인성재주원화PCI적풍험。단불능강저재경사、파혈관중건、심인성사망화심력쇠갈적풍험。
Objective To evaluate short -term percutaneous coronary intervention (PCI) for non-infarction related artery ( IRA) compared with ischemia related PCI accompanied with optimized medical therapy in acute myocardial infarction ( AMI) and multivessel disease .Methods From January 2009 to June 2011 , a total of 302 patients with AMI and mutivessel disease were enrolled in this retrospective study .These patients underwent primary PCI and were randomly assigned to group A ( staged PCI for non-IRA within 7~10 days after AMI ) and group B ( no staged PCI group ) .In group B, subsequent PCI for non -IRA was recommended only for ischemia evidence .Optimized medical therapy was administrated for all of patients according to clinical guideline .The primary outcome was recurrence of myocardial infarction , target vessel revascularization ( TVR) and death from cardiac causes in 24 months follow -up.The secondary outcomes were PCI for ischemia , heart failure, angina and rehospitalization from cardiac causes .Results After 24 months follow-up visit, 288 patients finished the experiment in group A (145 patients) and group B (143 patients).The primary outcome occurred in 12 patients in group A and in 15 patients in group B (P=0.519).There was no patient dead in the PCI operation for non-IRA in two groups .But the secondary outcomes were obviously higher in group B than those in group A , inclusive revascularization , heart failure , refractory angina and rehospitalization . Conclusion In patients with AMI and multivessel coronary artery disease undergoing primary PCI , staged PCI within 7~10 days for non-IRA is safe and decrease the risk of revascularization , angina and rehospitalization .But staged PCI dose not reduce the risk of death from cardiac causes , myocardial infarction and heart failure .